MX2021003262A - Metodos de tratamiento. - Google Patents

Metodos de tratamiento.

Info

Publication number
MX2021003262A
MX2021003262A MX2021003262A MX2021003262A MX2021003262A MX 2021003262 A MX2021003262 A MX 2021003262A MX 2021003262 A MX2021003262 A MX 2021003262A MX 2021003262 A MX2021003262 A MX 2021003262A MX 2021003262 A MX2021003262 A MX 2021003262A
Authority
MX
Mexico
Prior art keywords
treatment methods
methods
cancer
compositions
tumor antigens
Prior art date
Application number
MX2021003262A
Other languages
English (en)
Inventor
Jessica Baker Flechtner
Marie Lossky-Elias
Pamela M Carroll
Hubert Lam
Lisa K Mcneil
Wendy Jane Broom
Original Assignee
Genocea Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genocea Biosciences Inc filed Critical Genocea Biosciences Inc
Publication of MX2021003262A publication Critical patent/MX2021003262A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/57—Skin; melanoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/46449—Melanoma antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/57—IFN-gamma
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

En la presente se proporcionan métodos y composiciones para identificar antígenos tumorales de linfocitos humanos y para tratar sujetos que tienen cáncer.
MX2021003262A 2018-09-27 2019-09-27 Metodos de tratamiento. MX2021003262A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862737862P 2018-09-27 2018-09-27
PCT/US2019/053669 WO2020069452A1 (en) 2018-09-27 2019-09-27 Treatment methods

Publications (1)

Publication Number Publication Date
MX2021003262A true MX2021003262A (es) 2021-07-15

Family

ID=69953226

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021003262A MX2021003262A (es) 2018-09-27 2019-09-27 Metodos de tratamiento.

Country Status (14)

Country Link
US (1) US20230041057A1 (es)
EP (1) EP3856207A4 (es)
JP (1) JP2022502433A (es)
KR (1) KR20210091137A (es)
CN (1) CN113194967A (es)
AU (1) AU2019351273A1 (es)
BR (1) BR112021005596A2 (es)
CA (1) CA3113259A1 (es)
CO (1) CO2021005207A2 (es)
EA (1) EA202190862A1 (es)
IL (1) IL281792A (es)
MX (1) MX2021003262A (es)
SG (1) SG11202102878TA (es)
WO (1) WO2020069452A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111491655A (zh) 2017-08-07 2020-08-04 加利福尼亚大学董事会 用于生成安全细胞治疗剂的平台
CN115023270A (zh) * 2019-11-27 2022-09-06 迈斯特治疗公司 使用调节剂产生肿瘤反应性t细胞组合物的方法
CN113278731A (zh) * 2021-05-12 2021-08-20 广西医科大学 用于判断HIV-1感染者抗病毒治疗效果的lncRNA标志物及其应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003265948B8 (en) * 2002-09-06 2009-09-03 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Immunotherapy with in vitro-selected antigen-specific lymphocytes after nonmyeloablative lymphodepleting chemotherapy
ZA200602941B (en) * 2003-11-13 2007-07-25 Genentech Inc Screening assays and methods of tumor treatment
EP1765988B1 (en) * 2004-05-27 2017-09-20 The Trustees of The University of Pennsylvania Novel artificial antigen presenting cells and uses therefor
EP2327763B1 (en) * 2005-08-05 2018-03-14 Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt GmbH Generation of antigen specific T cells
JP2010235611A (ja) * 2010-05-10 2010-10-21 Ortho Mcneil Pharmaceut Inc 腫瘍の治療のための細胞治療方法
WO2015120198A1 (en) * 2014-02-05 2015-08-13 Cedars-Sinai Medical Center Methods and compositions for treating cancer and infectious diseases
TWI742008B (zh) * 2015-11-02 2021-10-11 美商健生生物科技公司 使用特異性結合ｃｄ３８之抗體免疫調節及治療固態腫瘤

Also Published As

Publication number Publication date
CO2021005207A2 (es) 2021-07-30
EP3856207A1 (en) 2021-08-04
AU2019351273A1 (en) 2021-05-20
WO2020069452A1 (en) 2020-04-02
BR112021005596A2 (pt) 2021-06-29
CN113194967A (zh) 2021-07-30
SG11202102878TA (en) 2021-04-29
JP2022502433A (ja) 2022-01-11
US20230041057A1 (en) 2023-02-09
EA202190862A1 (ru) 2021-07-07
KR20210091137A (ko) 2021-07-21
IL281792A (en) 2021-05-31
EP3856207A4 (en) 2022-11-16
CA3113259A1 (en) 2020-04-02

Similar Documents

Publication Publication Date Title
MX2019011148A (es) Metodos de tratamiento.
PH12020551923A1 (en) Methods and compositions for treating cancer
MX2020012797A (es) Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso.
MX2020008882A (es) Dosificación para tratamiento con anticuerpos antagonistas anti-tigit y anti-pd-l1.
MX2017005258A (es) Terapia combinada para tratamiento de enfermedad.
EA201792191A1 (ru) Комбинированная терапия fgfr/pd-1 для лечения злокачественной опухоли
MX2018008426A (es) Combinaciones anti-egfr para tratar tumores.
EA201691866A1 (ru) Проникающие в опухоль лимфоциты для адоптивной клеточной терапии
NZ725487A (en) Combination of lenalidomide or pomalidomide and cd38 antibody-attenuated interferon-alpha constructs, and the use thereof
MX2018016183A (es) Anticuerpos especificos del ligando 1 de muerte programada y metodos de uso de los mismos.
EA201890957A1 (ru) Комбинированная терапия для лечения злокачественных опухолей
MX2021003262A (es) Metodos de tratamiento.
MX2019003722A (es) Composiciones inmunogénicas de tert y métodos de tratamiento que las utilizan.
MX2019006331A (es) Métodos para tratar el cáncer usando anticuerpos anti-pd-l1 y antiandrógenos.
ZA201907225B (en) Treatment of her2 positive cancers
PH12021551036A1 (en) Anti-liv1 immune cell cancer therapy
MX2020006297A (es) Variantes de cd19.
WO2017040666A3 (en) Combination therapy for treatment of disease
ZA202202363B (en) Antibodies against ilt2 and use thereof
MX2019008233A (es) Nanoconjugados de doxorrubicina y oro dirigidos para terapia tumoral.
MX2018009499A (es) Anticuerpos monoclonales especificos de egfl6 y metodos de su uso.
MX2021003265A (es) Metodos de tratamiento.
EP3371211A4 (en) METHOD FOR THE TREATMENT OF TUMORS AND CANCER AND IDENTIFICATION OF CANDIDATE PATIENTS FOR SUCH TREATMENT
SA521422250B1 (ar) أجسام مضادة للبيريوستين واستخداماتها
MX2022014180A (es) Metodos, terapias y usos para tratar cancer.